CANCER IMMUNOTHERAPY The dark side of PD-1 receptor inhibition

Editorial Material

关键词: NIVOLUMAB;   

DOI  :  10.1038/nature24759

来源: SCIE

【 摘 要 】

Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves.

【 授权许可】

Free